| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Steven Gillis is Director at QTTB, with reported holdings spanning 3 companies. Steven Gillis's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $58.2M at current prices.
Steven Gillis's largest disclosed position is in QTTB as Director, worth about $53.2M.
Steven Gillis has 18 Form 4 filings on record from June 2015 to July 2026, across 3 companies: Director at Takeda Pharmaceutical (TKPHF), 2026; Director at QTTB, 2018–2023; Pulmatrix (PULM), 2015–2020.
The 40 reported transactions were 24 option or other derivative awards, 9 dispositions back to the company, 4 open-market purchases and 2 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $500K and no sales.
The only open-market purchase was 72,750 shares of PULM at an average $6.88 on June 16, 2015, about $500K.